8F8 Stock Chart & Stats
€2.08
€0.06(6.50%)
At close: 4:00 PM EST
€2.08
€0.06(6.50%)
Day’s Range― - ―
52-Week Range€0.97 - €2.32
Previous CloseN/A
Volume0.00
Average Volume (3M)89.00
Market Cap
€89.65M
Enterprise Value€501.49M
Total Cash (Recent Filing)€65.78M
Total Debt (Recent Filing)€1.07M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.14
Shares Outstanding53,330,242
10 Day Avg. Volume268
30 Day Avg. Volume89
Financial Highlights & Ratios
PEG Ratio-2.41
Price to Book (P/B)6.78
Price to Sales (P/S)0.00
P/FCF Ratio-11.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low debt and a meaningful equity base materially reduce short-term solvency risk and provide a durable financing buffer. This conservatism extends runway flexibility for R&D and decreases refinancing pressure, supporting strategy execution through clinical milestones.
Focused Clinical-stage Immunology ProgramA clear, focused lead program targeting inflammation via a novel receptor agonist concentrates scientific resources and IP. Success in clinical readouts would create durable value drivers (licensing, partnerships, commercialization) and leverages a defensible niche in immunology.
Improving Cash Burn TrendA reduction in cash burn and positive TTM free cash flow growth signal improving operational control. If sustained, this trend lengthens runway, lowers near-term financing frequency, and shows management can tune spending to milestone timing while advancing clinical programs.
Bears Say
No Commercial Revenue And Large LossesThe company is pre-commercial with no recurring sales; persistent large net losses make long-term viability contingent on clinical success or external funding. Without revenue, value creation relies on binary R&D outcomes, raising execution and funding risk over months.
Persistent Negative Operating And Free Cash FlowSustained negative operating and free cash flow imply ongoing cash burn to sustain R&D. This structural outflow necessitates repeated financing or asset monetization, increasing dilution risk and potentially forcing timing or scope changes to development programs.
Dependence On External Financing And PartnershipsWith no commercial cash flows, the business model depends on licensing deals, collaborations, or equity raises. That creates binary outcomes and timing uncertainty; negotiating leverage is limited pre-approval, raising strategic and dilutionary risks if markets or partners are constrained.
SynAct Pharma AB News
8F8 FAQ
What was SynAct Pharma AB’s price range in the past 12 months?
SynAct Pharma AB lowest stock price was €0.97 and its highest was €2.32 in the past 12 months.
What is SynAct Pharma AB’s market cap?
SynAct Pharma AB’s market cap is €89.65M.
When is SynAct Pharma AB’s upcoming earnings report date?
SynAct Pharma AB’s upcoming earnings report date is Aug 20, 2026 which is in 29 days.
How were SynAct Pharma AB’s earnings last quarter?
SynAct Pharma AB released its earnings results on May 27, 2026. The company reported -€0.044 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.044.
Is SynAct Pharma AB overvalued?
According to Wall Street analysts SynAct Pharma AB’s price is currently Overvalued.
Does SynAct Pharma AB pay dividends?
SynAct Pharma AB does not currently pay dividends.
What is SynAct Pharma AB’s EPS estimate?
SynAct Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SynAct Pharma AB have?
SynAct Pharma AB has 53,330,242 shares outstanding.
What happened to SynAct Pharma AB’s price movement after its last earnings report?
SynAct Pharma AB reported an EPS of -€0.044 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 12.789%.
Which hedge fund is a major shareholder of SynAct Pharma AB?
Currently, no hedge funds are holding shares in DE:8F8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SynAct Pharma AB
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Örebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.
Technical Analysis
Oncopeptides AB
―
Saniona AB
―
Ascelia Pharma AB
―
Guard Therapeutics International AB
―
Cantargia AB
―